Biocon Biologics clears Yesafili worldwide launches 2026

Overview of the new settlement

Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE: 532523, NSE: BIOCON), said it has signed a new settlement and licence agreement with Regeneron and Bayer for biosimilar aflibercept (40mg/ml) across Europe and the rest of the world. The company said the arrangement follows an earlier settlement that covered the United States and Canada. With the latest agreement in place, Biocon Biologics said it can commercialise Yesafili, its biosimilar aflibercept (40mg/ml), in all countries worldwide. The parties also executed the agreement to dismiss all pending litigation related to the matter. The company said the other terms of the settlement are confidential.

What the agreement changes for Yesafili’s global rollout

The key change is legal clarity on where and when Yesafili can be launched. Biocon Biologics said the settlement enables it to launch YESAFILI in the United Kingdom in January 2026. For the rest of the settled countries, the company said the launch window is March 2026, or earlier in certain circumstances. Separately, the company has already described market-entry timing for North America through earlier settlements. Put together, the announcements create a clearer, market-by-market path for the product’s commercialisation.

Europe and UK: launch windows now specified

Biocon Biologics said the latest settlement covers Europe and the rest of the world. The company specified the UK as the first European market in this schedule, with a launch in January 2026. It also set March 2026 as the launch window for the “rest of the settled countries”, with language that it could be earlier in certain circumstances. The company did not disclose commercial or financial terms for these regions, stating that the other terms are confidential.

United States: earlier settlement supports H2 2026 entry

For the United States, Biocon Biologics has said it secured market entry in April 2025, with timing set for the second half of calendar year 2026 or earlier in certain circumstances. In a separate update carried by PTI, the company said it inked a settlement and licensing pact with Regeneron, paving the way to commercialise Yesafili in the US. It added that the settlement enabled dismissal of a pending appeal at the US Court of Appeals for the Federal Circuit (USCAFC) and pending litigation at the US District Court for the Northern District of West Virginia, Clarksburg Division. The company has also stated the settlement resolves litigation concerning the ‘865 patent.

Canada: approval and launch timeline disclosed

Biocon Biologics said YESAFILI was launched in Canada earlier this year, and that market entry for Canada was secured in March 2024. In a separate company update dated June 27, 2025, Biocon Biologics said Health Canada granted a Notice of Compliance (NOC) for Yesafili (aflibercept) on June 26, 2025, in vial and prefilled syringe presentations, 2 mg/0.05 mL. The company said this approval paves the way for the launch of YESAFILI in Canada, scheduled for July 4, 2025. It also said YESAFILI is the first biosimilar to EYLEA to be approved by Health Canada. Other reporting in the provided material also states Biocon Biologics reached a settlement in Canada with Bayer Inc and Regeneron Pharmaceuticals, Inc. for launch no later than July 1, 2025.

Regulatory backdrop: approvals already in place

Biocon Biologics said the US Food and Drug Administration approved YESAFILI (aflibercept-jbvf) as an interchangeable biosimilar in May 2024. The company also described this as its first-to-file application for Yesafili. In its May 21, 2024 update, Biocon Biologics said the approval marked its expansion into ophthalmology in the United States, following approvals in Europe (September 2023) and the United Kingdom (November 2023), where it said it was the first biosimilar aflibercept to be approved. The company said the approval was supported by a package of analytical, nonclinical and clinical data confirming high similarity to Eylea (aflibercept).

What Yesafili treats and how it is positioned

Biocon Biologics describes YESAFILI as a vascular endothelial growth factor (VEGF) inhibitor and a biosimilar of EYLEA (aflibercept). The product is intended for the treatment of neovascular (wet) age-related macular degeneration (wet AMD), visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO), visual impairment due to diabetic macular oedema (DME), and visual impairment due to myopic choroidal neovascularisation (myopic CNV). The company’s May 2024 disclosure also lists diabetic retinopathy (DR) as an indicated condition. It also states contraindications include ocular or periocular infection, active intraocular inflammation, and hypersensitivity to aflibercept.

Key dates and market-entry milestones

Stock reaction and investor reference points

Biocon’s shares moved after the US settlement-related announcement, with one report stating the stock closed at Rs 329.45, up 4.08% from the previous trading day. Another report said the stock rose 3.29% to Rs 326.95 on the BSE after the agreement was announced. A separate data point in the provided material said the stock opened at ₹321.00, hit a high of ₹327.00 and a low of ₹319.70 during the session. The material also cites InvestingPro, which put Biocon’s fair value at INR 360.7 per share versus a current market price of INR 326.8, implying a 10.5% upside.

Why this matters for Biocon Biologics’ biosimilars strategy

The settlements remove litigation overhang in multiple geographies and set specific launch windows, which is operationally important for a biosimilar that targets large ophthalmology indications. The worldwide scope stated in the Europe and rest-of-world settlement, together with earlier North America timelines, creates a more complete commercial pathway for Yesafili. The company has also highlighted interchangeability in the US, which matters because it is positioned to allow substitution for the reference product without physician intervention, as described in the supplied material. At the same time, Biocon Biologics has kept financial terms confidential, so the disclosures are primarily about legal clearance, timing, and regulatory status rather than economics.

Conclusion

Biocon Biologics’ latest settlement with Regeneron and Bayer extends legal clearance for Yesafili to Europe and the rest of the world, complementing earlier settlements for the US and Canada. The company has now disclosed launch windows of January 2026 for the UK and March 2026 for other settled countries, alongside a stated H2 2026 timing for the US and a scheduled July 4, 2025 launch in Canada following Health Canada’s NOC. Further updates, if any, are likely to focus on country-level rollout execution within these disclosed windows, as the settlement’s commercial terms remain confidential.